keyword
Keywords immunity therapy for cholangio...

immunity therapy for cholangiocarcinoma

https://read.qxmd.com/read/38203714/current-and-emerging-therapeutic-targets-for-the-treatment-of-cholangiocarcinoma-an-updated-review
#21
REVIEW
Matthew J Hadfield, Kathryn DeCarli, Kinan Bash, Grace Sun, Khaldoun Almhanna
Cholangiocarcinoma is a malignancy of the bile ducts that is often associated with late diagnosis, poor overall survival, and limited treatment options. The standard of care therapy for cholangiocarcinoma has been cytotoxic chemotherapy with modest improvements in overall survival with the addition of immune checkpoint inhibitors. The discovery of actionable mutations has led to the advent of targeted therapies against FGFR and IDH-1, which has expanded the treatment landscape for this patient population. Significant efforts have been made in the pre-clinical space to explore novel immunotherapeutic approaches, as well as antibody-drug conjugates...
December 30, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38203635/molecular-profile-of-intrahepatic-cholangiocarcinoma
#22
REVIEW
Wellington Andraus, Francisco Tustumi, José Donizeti de Meira Junior, Rafael Soares Nunes Pinheiro, Daniel Reis Waisberg, Liliana Ducatti Lopes, Rubens Macedo Arantes, Vinicius Rocha Santos, Rodrigo Bronze de Martino, Luiz Augusto Carneiro D'Albuquerque
Intrahepatic cholangiocarcinoma (ICC) is a relatively uncommon but highly aggressive primary liver cancer that originates within the liver. The aim of this study is to review the molecular profile of intrahepatic cholangiocarcinoma and its implications for prognostication and decision-making. This comprehensive characterization of ICC tumors sheds light on the disease's underlying biology and offers a foundation for more personalized treatment strategies. This is a narrative review of the prognostic and therapeutic role of the molecular profile of ICC...
December 29, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38177560/current-standards-multidisciplinary-approaches-and-future-directions-in-the-management-of-extrahepatic-cholangiocarcinoma
#23
REVIEW
Margaret Wheless, Rajiv Agarwal, Laura Goff, Natalie Lockney, Chandrasekhar Padmanabhan, Thatcher Heumann
Biliary tract cancers are molecularly and anatomically diverse cancers which include intrahepatic cholangiocarcinoma, extrahepatic (perihilar and distal) cholangiocarcinoma, and gallbladder cancer. While recognized as distinct entities, the rarer incidence of these cancers combined with diagnostic challenges in classifying anatomic origin has resulted in clinical trials and guideline recommended strategies being generalized patients with all types of biliary tract cancer. In this review, we delve into the unique aspects, subtype-specific clinical trial outcomes, and multidisciplinary management of patients with extrahepatic cholangiocarcinoma...
January 5, 2024: Current Treatment Options in Oncology
https://read.qxmd.com/read/38128340/advances-and-considerations-in-the-use-of-immunotherapies-for-primary-hepato-biliary-malignancies
#24
REVIEW
Leva Gorji, Zachary J Brown, Timothy M Pawlik
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) comprise the two most common primary liver malignancies. Curative treatment options often include hepatectomy or liver transplantation; however, many patients present with advanced disease that is not amenable to surgical management. In turn, many patients are treated with systemic or targeted therapy. The tumor microenvironment (TME) is a complex network of immune cells and somatic cells, which can foster an environment for disease development and progression, as well as susceptibility and resistance to systemic therapeutic agents...
February 2024: Surgical Oncology
https://read.qxmd.com/read/38125756/non-coding-rna-and-drug-resistance-in-cholangiocarcinoma
#25
REVIEW
Zhaowei Wu, Shiming Jiang, Yong Chen
Cholangiocarcinoma is a highly aggressive cancer with a dismal prognosis and limited resectability. Chemotherapy has demonstrated tremendous benefits for patients with advanced and inoperable cancer, but drug resistance poses a significant obstacle. Despite recent progress in cancer therapy, the mechanisms driving drug resistance are multifaceted and not completely comprehended. Non-coding RNA refers to RNA molecules that are endogenous and do not code for proteins. Particularly microRNAs, long non-coding RNAs, circular RNAs, are widely acknowledged to be involved in cancer initiation, proliferation, and metastasis...
March 2024: Non-Coding RNA Research
https://read.qxmd.com/read/38124204/alox5-acts-as-a-key-role-in-regulating-the-immune-microenvironment-in-intrahepatic-cholangiocarcinoma-recruiting-tumor-associated-macrophages-through-pi3k-pathway
#26
JOURNAL ARTICLE
Jialu Chen, Yue Tang, Delong Qin, Xiaopeng Yu, Huanjun Tong, Chengwei Tang, Zhaohui Tang
BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is poorly treated due to the presence of an inhibitory immune microenvironment. Tumor-associated macrophages (TAM) are an important component of TME. ALOX5 is an important lipid metabolism enzyme in cancer progression, but the mechanism by which it regulates TAM to promote ICC progression is unknown. The aim of this study was to investigate the potential mechanism of TAM regulation by ALOX5 and the translational effect of targeting ALOX5...
December 20, 2023: Journal of Translational Medicine
https://read.qxmd.com/read/38077645/response-of-cholangiocarcinoma-with-epigastric-metastasis-to-lenvatinib-plus-sintilimab-a-case-report-and-review-of-literature
#27
Wen-Hui Luo, Shao-Jun Li, Xue-Feng Wang
BACKGROUND: Cholangiocarcinoma (CCA) poses a significant clinical challenge due to its low radical resection rate and a propensity for high postoperative recurrence, resulting in a poor dismal. Although the combination of targeted therapy and immunotherapy has demonstrated notable efficacy in several solid tumors recently, however, its application in CCA remains underexplored and poorly documented. CASE SUMMARY: This case report describes a patient diagnosed with stage IV CCA, accompanied by liver and abdominal wall metastases, who underwent palliative surgery...
November 15, 2023: World Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38050079/integrative-multiomics-enhancer-activity-profiling-identifies-therapeutic-vulnerabilities-in-cholangiocarcinoma-of-different-etiologies
#28
JOURNAL ARTICLE
Jing Han Hong, Chern Han Yong, Hong Lee Heng, Jason Yongsheng Chan, Mai Chan Lau, Jianfeng Chen, Jing Yi Lee, Abner Herbert Lim, Zhimei Li, Peiyong Guan, Pek Lim Chu, Arnoud Boot, Sheng Rong Ng, Xiaosai Yao, Felicia Yu Ting Wee, Jeffrey Chun Tatt Lim, Wei Liu, Peili Wang, Rong Xiao, Xian Zeng, Yichen Sun, Joanna Koh, Xiu Yi Kwek, Cedric Chuan Young Ng, Poramate Klanrit, Yaojun Zhang, Jiaming Lai, David Wai Meng Tai, Chawalit Pairojkul, Simona Dima, Irinel Popescu, Sen-Yung Hsieh, Ming-Chin Yu, Joe Yeong, Sarinya Kongpetch, Apinya Jusakul, Watcharin Loilome, Patrick Tan, Jing Tan, Bin Tean Teh
OBJECTIVES: Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling. DESIGN: Integrative multiomics enhancer activity profiling of diverse CCA was performed...
November 24, 2023: Gut
https://read.qxmd.com/read/38043787/correlation-of-vein-rich-tumor-microenvironment-of-intrahepatic-cholangiocarcinoma-with-tertiary-lymphoid-structures-and-patient-outcome
#29
JOURNAL ARTICLE
Noriteru Doi, Yoshinori Ino, Masanori Fuse, Minoru Esaki, Kazuaki Shimada, Nobuyoshi Hiraoka
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive cancer composed of large-duct and small-duct types. Understanding the tumor immune microenvironment and its related vascular system is important for developing novel and efficient therapies. We focused on tertiary lymphoid structure (TLS) as a hallmark of antitumor immunity and investigated the clinicopathological significance of TLSs and the influence of vascular microenvironment on TLS formation in iCCAs. We examined 261 iCCA cases clinicopathologically and analyzed the vascular system using immunohistochemistry...
December 1, 2023: Modern Pathology
https://read.qxmd.com/read/38036041/spatial-multimodal-analysis-revealed-tertiary-lymphoid-structures-as-a-risk-stratification-indicator-in-combined-hepatocellular-cholangiocarcinoma
#30
JOURNAL ARTICLE
Xiaojie Gan, Wei Dong, Wenhua You, Dongyang Ding, Yuan Yang, Dapeng Sun, Wen Li, Wenbin Ding, Yuan Liang, Fu Yang, Weiping Zhou, Hui Dong, Shengxian Yuan
The microenvironment created by tertiary lymphoid structures (TLSs) can support and regulate immune responses, affecting the prognosis and immune treatment of patients. Nevertheless, the actual importance of TLSs for predicting the prognosis of combined hepatocellular-cholangiocarcinoma (cHCC-CCA) patients remains unclear. Herein, using spatial transcriptomic analysis, we revealed that a gene signature of TLSs specific to cHCC-CCA was associated with high-intensity immune infiltration. Then, a novel scoring system was developed to evaluate the distribution and frequency of TLSs in intra-tumoral and extra-tumoral regions (iTLS and eTLS scores) in 146 cHCC-CCA patients...
November 28, 2023: Cancer Letters
https://read.qxmd.com/read/37985959/unveiling-the-immunogenomic-landscape-of-cholangiocarcinoma-identifying-new-prognostic-markers-and-therapeutic-targets-based-on-ccl5-expression
#31
JOURNAL ARTICLE
Jing Wang, Dan Xiang, Zhe Dai, Jialong Zhu, Yuanyang Du, Gongbo Fu, Xiaoyuan Chu
BACKGROUND: Cholangiocarcinoma (CCA) stands as an aggressive malignancy of the biliary tract. The interplay between the tumor and immune system plays a pivotal role in disease progression and treatment outcomes. Hence, the present study aimed to extensively explore the immunogenomic landscape of CCA, with the objective of unveiling unique molecular and immunological signatures that could guide personalized therapeutic approaches. METHODS: The study collected data from The Cancer Genome Atlas databases, performed gene set variation analysis for the chemokine ligand 5 (CCL5) high/low expression group, conducted principal component analysis, gene set enrichment analysis enrichment and mutation pattern analysis, generated a heatmap, and performed cox regression analysis...
November 20, 2023: Journal of Gene Medicine
https://read.qxmd.com/read/37975978/molecular-profiling-and-prognostic-analysis-in-chinese-cholangiocarcinoma-an-observational-retrospective-single-center-study
#32
JOURNAL ARTICLE
Changkun Zhang, Xia You, Qin Zhang, Dong Wang
Cholangiocarcinoma (CCA) is a primary malignancy which is often diagnosed when it is advanced and inoperable due to the lack of effective biomarkers and poor sensitivity of clinical diagnosis. Molecular profiling may provide information for improved clinical management, particularly targeted therapy. The study aimed to improve the understanding of molecular characteristics and its association with prognosis in Chinese CCA. We enrolled 41 Chinese patients with CCA, including 6 intrahepatic CCA (iCCA), 14 perihilar CCA (pCCA), and 21 distal CCA (dCCA) cases, all patients underwent radical operations and tumor samples underwent next-generation sequencing (NGS) by Foundation One Dx, which analyzed 324 genes...
November 17, 2023: Investigational New Drugs
https://read.qxmd.com/read/37939617/enhancing-cholangiocarcinoma-immunotherapy-with-adoptive-t-cells-targeting-hla-restricted-neoantigen-peptides-derived-from-driver-gene-mutations
#33
JOURNAL ARTICLE
Aussara Panya, Chutamas Thepmalee, Nunghathai Sawasdee, Sasithorn Saengmuang, Piriya Luangwattananun, Pa-Thai Yenchitsomanus
Precision immunotherapy, driven by genomic and bioinformatic advancements, has emerged as a promising and viable approach to combat cancer. Targeting neoantigens offers the advantage of specific immune responses with minimal off-tumor toxicity. In this study, we investigated the potential of adoptive T cells activated by HLA-restricted neoantigen peptides from driver gene mutations for treating cholangiocarcinoma (CCA), a highly aggressive cancer with poor prognosis and high mortality rates. Through whole exome sequencing of CCA cell lines, KKU-213A and KKU-100, we identified mutations in common driver genes and predicted corresponding HLA-restricted peptides...
November 6, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37900166/case-report-remarkable-response-to-sintilimab-lenvatinib-and-nab-paclitaxel-in-postoperative-metastatic-chemotherapy-resistant-combined-hepatocellular-cholangiocarcinoma
#34
Nan Zhou, Chuan-Fen Lei, Si-Rui Tan, Qi-Yue Huang, Shun-Yu Zhang, Zheng-Xin Liang, Hong-Feng Gou
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a highly aggressive malignancy with a poor prognosis. However, there are no consensus treatment guidelines, and decisions are usually extrapolated from intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC). Given that cHCC-CCA owns the unequivocal presence of both hepatocytic and cholangiocytic differentiation, a combination regimen of anti-PD1 antibody, multikinase inhibitor, and chemotherapy targeting against both components might be an optimal choice...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37894256/interplay-between-the-human-microbiome-and-biliary-tract-cancer-implications-for-pathogenesis-and-therapy
#35
REVIEW
Cheng Ye, Chunlu Dong, Yanyan Lin, Huaqing Shi, Wence Zhou
Biliary tract cancer, encompassing intrahepatic and extrahepatic cholangiocarcinoma as well as gallbladder carcinoma, stands as a prevalent malignancy characterized by escalating incidence rates and unfavorable prognoses. The onset of cholangiocarcinoma involves a multitude of risk factors and could potentially be influenced by microbial exposure. The human microbiome, encompassing the entirety of human microbial genetic information, assumes a pivotal role in regulating key aspects such as host digestion, absorption, immune responses, and metabolism...
October 20, 2023: Microorganisms
https://read.qxmd.com/read/37888583/tumor-immune-microenvironment-and-the-current-immunotherapy-of-cholangiocarcinoma-review
#36
JOURNAL ARTICLE
Siqi Yang, Ruiqi Zou, Yushi Dai, Yafei Hu, Fuyu Li, Haijie Hu
Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy originating from the epithelial system of the bile ducts, and its incidence in recent years is steadily increasing. The immune microenvironment of CCA is characterized by diversity and complexity, with a substantial presence of cancer‑associated fibroblasts and immune cell infiltration, which plays a key role in regulating the distinctive biological behavior of cholangiocarcinoma, including tumor growth, angiogenesis, lymphangiogenesis, invasion and metastasis...
December 2023: International Journal of Oncology
https://read.qxmd.com/read/37886181/conversion-therapy-for-advanced-cholangiocarcinoma-in-the-era-of-molecular-targeted-therapy-and-immune-therapy
#37
EDITORIAL
Zunyi Zhang, Wei Zhang
No abstract text is available yet for this article.
October 1, 2023: Hepatobiliary Surgery and Nutrition
https://read.qxmd.com/read/37828105/exploration-of-a-screening-model-for-intrahepatic-cholangiocarcinoma-patients-prone-to-cuproptosis-and-mechanisms-of-the-susceptibility-of-cd274-knockdown-intrahepatic-cholangiocarcinoma-cells-to-cuproptosis
#38
JOURNAL ARTICLE
Zefeng Shen, Jingwei Cai, Liye Tao, Junhao Zheng, Zhengtao Ye, Yang Liu, Haoyu Pan, Yali Wang, Junjie Xu, Xiao Liang
Intrahepatic cholangiocarcinoma (ICC) is a form of liver cancer with poor long-term survival rates that requires novel therapeutic methods. Our team's previous research found that ICC patients prone to cuproptosis possessed a more satisfactory long-term prognosis and a more sensitive response to copper carrier Elesclomol. Thus, we aimed to identify new diagnostic and treatment strategies for ICC patients prone to cuproptosis and further explore the associated intracellular and extracellular mechanisms of ICC cells prone to cuproptosis...
October 12, 2023: Cancer Gene Therapy
https://read.qxmd.com/read/37806285/patient-derived-precision-cut-tissue-slices-from-primary-liver-cancer-as-a-potential-platform-for-preclinical-drug-testing
#39
JOURNAL ARTICLE
Ravi Jagatia, Ewald J Doornebal, Una Rastovic, Nicola Harris, Moyosoreoluwa Feyide, Anabel Martinez Lyons, Rosa Miquel, Yoh Zen, Ane Zamalloa, Farooq Malik, Andreas Prachalias, Krishna Menon, Luke Boulter, Simon Eaton, Nigel Heaton, Sandra Phillips, Shilpa Chokshi, Elena Palma
BACKGROUND: The exploitation of anti-tumour immunity, harnessed through immunomodulatory therapies, has fundamentally changed the treatment of primary liver cancer (PLC). However, this has posed significant challenges in preclinical research. Novel immunologically relevant models for PLC are urgently required to improve the translation from bench to bedside and back, explore and predict effective combinatorial therapies, aid novel drug discovery and develop personalised treatment modalities...
October 6, 2023: EBioMedicine
https://read.qxmd.com/read/37771368/the-role-of-ischaemia-reperfusion-injury-and-liver-regeneration-in-hepatic-tumour-recurrence
#40
REVIEW
Marianna Maspero, Sumeyye Yilmaz, Beatrice Cazzaniga, Roma Raj, Khaled Ali, Vincenzo Mazzaferro, Andrea Schlegel
The risk of cancer recurrence after liver surgery mainly depends on tumour biology, but preclinical and clinical evidence suggests that the degree of perioperative liver injury plays a role in creating a favourable microenvironment for tumour cell engraftment or proliferation of dormant micro-metastases. Understanding the contribution of perioperative liver injury to tumour recurrence is imperative, as these pathways are potentially actionable. In this review, we examine the key mechanisms of perioperative liver injury, which comprise mechanical handling and surgical stress, ischaemia-reperfusion injury, and parenchymal loss leading to liver regeneration...
November 2023: JHEP reports: innovation in hepatology
keyword
keyword
170425
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.